InsiderTrades.com logo

VACC Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 6.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Vaccitech Insider Trading History Chart

This chart shows the insider buying and selling history at Vaccitech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaccitech Share Price & Price History

Current Price: $0.72
Price Change: ▼ Price Decrease of -0.019 (-2.57%)
As of 12/4/2025 01:00 AM ET

This chart shows the closing price history over time for VACC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Vaccitech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/26/2023Joseph ScheerenDirectorBuy10,000$2.44$24,400.0023,000View SEC Filing Icon  
5/25/2023Robin WrightDirectorBuy13,750$2.66$36,575.0048,256View SEC Filing Icon  
3/27/2023William EnrightCEOSell15,000$2.42$36,300.00728,454View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Vaccitech (NASDAQ:VACC)

26.13% of Vaccitech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VACC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Vaccitech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/10/2024M&G Plc5,197,349$25.99M0.2%N/A13.483%Search for SEC Filing on Google Icon
1/31/2024Ipswich Investment Management Co. Inc.23,075$0.12M0.0%-14.8%0.060%Search for SEC Filing on Google Icon
11/8/2023Janney Montgomery Scott LLC15,008$46K0.0%N/A0.039%Search for SEC Filing on Google Icon
5/15/2023Liontrust Investment Partners LLP455,848$1.02M0.0%-24.0%1.189%Search for SEC Filing on Google Icon
4/24/2023Ipswich Investment Management Co. Inc.27,075$61K0.0%+26.7%0.071%Search for SEC Filing on Google Icon
11/16/2022Alphabet Inc.1,513,644$4.84M0.2%N/A4.058%Search for SEC Filing on Google Icon
11/1/2022M&G Investment Management Ltd.5,197,349$15.59M0.1%+377.4%13.964%Search for SEC Filing on Google Icon
10/11/2022Ipswich Investment Management Co. Inc.23,475$75K0.0%-41.3%0.063%Search for SEC Filing on Google Icon
7/26/2022Ipswich Investment Management Co. Inc.39,975$0.18M0.1%-23.7%0.107%Search for SEC Filing on Google Icon
2/14/2022Johns Hopkins University107,968$1.20M0.1%N/A0.310%Search for SEC Filing on Google Icon
2/14/2022ETF Managers Group LLC10,087$0.11M0.0%-21.9%0.029%Search for SEC Filing on Google Icon
11/22/2021Liontrust Investment Partners LLP600,000$9.44M0.1%N/A1.720%Search for SEC Filing on Google Icon
11/16/2021Brookfield Asset Management Inc.15,921$0.25M0.0%-36.3%0.046%Search for SEC Filing on Google Icon
11/15/2021Tudor Investment Corp Et Al378,260$5.73M0.0%-10.0%1.102%Search for SEC Filing on Google Icon
11/15/2021Caas Capital Management LP10,251$0.16M0.0%-79.5%0.030%Search for SEC Filing on Google Icon
11/12/2021Ghisallo Capital Management LLC20,625$0.33M0.0%+106.3%0.060%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Vaccitech logo
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Read More on Vaccitech

Today's Range

Now: $0.72
Low: $0.72
High: $0.79

50 Day Range

MA: $1.57
Low: $1.19
High: $5.00

52 Week Range

Now: $0.72
Low: $1.64
High: $5.10

Volume

47,953 shs

Average Volume

244,643 shs

Market Capitalization

$27.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A